Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment
Open accessThe DOI matches its Crossref record; 224 of the 225 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, its precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine’s molecular actions. Ketamine primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, and increasing glutamate release. This enhanced glutamate activates AMPA receptors, triggering crucial downstream cascades, including BDNF-TrkB and mTOR pathways, promoting synaptic proliferation and regeneration. Moreover, neuroimaging studies have demonstrated alterations in brain networks involved in emotional regulation, including the Default Mode Network (DMN), Central Executive Network (CEN), and Salience Network (SN), which are frequently disrupted in depression. Despite the promising findings, the literature reveals significant inaccuracies and gaps in understanding the full scope of ketamine’s therapeutic potential. For instance, ketamine engages with opioid receptors, insinuating a permissive role of the opioid system in amplifying ketamine’s antidepressant effects, albeit ketamine does not operate as a direct opioid agonist. Further exploration is requisite to comprehensively ascertain its safety profile, long-term efficacy, and the impact of genetic determinants, such as BDNF polymorphisms, on treatment responsiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TrkB activation triggers ERK and mTORC1 cascades, extends protein synthesis windows, and supports dendritic spine maturation”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esketamine provides a more NMDAR-centered entry into the induction pathway described above, producing rapid clinical effects but also transient dissociation and sympathomimetic effects [45,46,47,49,52,55,56].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zolghadriha, A., Anjomshoaa, A., Jamshidi, M. R., & Taherkhani, F. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05716-0 · Cited by 35
RetractedMalhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099 · cited 1×
“It is characterized by a recurrent and chronic course and is associated with a high risk of suicidal thoughts and attempts [2–4].”
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“This inhibitory action subsequently liberates mTOR Complex 1 (mTORC1) from its regulatory constraints. mTORC1 then phosphorylates downstream targets including p70S6K and 4E-BP1 (see Figure 3) [105,143].”
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693 · cited 1×
“A series of magnetic resonance imaging (MRI) studies have shown a reduction in the volume of both the PFC and hippocampus by up to about 19% in patients with MDD [78,154,155], and positron emission tomography (PET) reduced metabolism in PFC [78,156].”
Estimating the true global burden of mental illness
Vigo, D., Thornicroft, G., & Atun, R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00505-2 · Cited by 2,494
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Risks of all-cause and suicide mortality in mental disorders: a meta-review
Chesney, E., Goodwin, G. M., & Fazel, S. (2014) · World Psychiatry · doi:10.1002/wps.20128 · Cited by 2,115 · cited 1×
“It is characterized by a recurrent and chronic course and is associated with a high risk of suicidal thoughts and attempts [2–4].”
Salience processing and insular cortical function and dysfunction
Uddin, L. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3857 · Cited by 2,083 · cited 1×
“It plays a critical role in integrating sensory and emotional information, and its activity is modulated by homeostatic, emotional, or cognitive factors [185,186].”
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 3×
“Moreover, ketamine’s activity-independent blockade of NMDARs reduces phosphorylation of eukaryotic elongation factor 2 (eEF2), which, in turn, enhances BDNF expression and supports synaptic formation [92,93].”
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 1×
“A growing number of clinical studies support the neurotrophic hypothesis of depression, which emphasizes the role of the PFC and hippocampus, including the disruption of neurotrophic factors and synaptic connections [213–215].”
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477 · cited 1×
“Postmortem analyses have also observed reduced neuronal size and thickness of the cerebral cortex, especially in the medial and orbital areas in the PFC [159,160], and fewer granule cells in the dentate gyrus of the hippocampus in depressed individuals [161,162].”
for the ENIGMA-Major Depressive Disorder Working Group, Schmaal, L., Hibar, D. P., Sämann, P. G., Hall, G. B., Baune, B. T., Jahanshad, N., Cheung, J. W., van Erp, T. G. M., Bos, D., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.60 · Cited by 1,330
Structure and Function of the Human Insula
Uddin, L. Q., Nomi, J. S., Hébert-Seropian, B., Ghaziri, J., & Boucher, O. (2017) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0000000000000377 · Cited by 1,262 · cited 1×
“It plays a critical role in integrating sensory and emotional information, and its activity is modulated by homeostatic, emotional, or cognitive factors [185,186].”
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 1×
“However, oral administration is associated with relatively low and highly variable bioavailability, ranging from 10% to 20% [49–51].”
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036
Hyperpolarization-Activated Cation Channels: From Genes to Function
Biel, M., Wahl-Schott, C., Michalakis, S., & Zong, X. (2009) · Physiological Reviews · doi:10.1152/physrev.00029.2008 · Cited by 1,003
Woolley, C., & McEwen, B. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02549.1992 · Cited by 990
Hol, E. M., & Pekny, M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.02.004 · Cited by 917
The Salience Network: A Neural System for Perceiving and Responding to Homeostatic Demands
Seeley, W. W. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1138-17.2019 · Cited by 845
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836 · cited 1×
“Approximately 30% of patients fail to respond to at least two classic antidepressants at the appropriate dose and duration ( ≥ 6 weeks), a condition referred to as treatment-resistant depression (TRD) [11].”
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808 · cited 1×
“The number of spinal synapses is also reduced in the PFC in MDD subjects [158,159].”
Postsynaptic BDNF‐TrkB signaling in synapse maturation, plasticity, and disease
Yoshii, A., & Constantine‐Paton, M. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20765 · Cited by 744
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739 · cited 1×
“In addition, the PFC affects the amygdala, which is responsible for the control of fear and anxiety, which is closely related to depression [219,220].”
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 1×
“The onset of action typically occurs within 5–40 min, with peak effects observed around 40 min post-administration [56,57].”
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711 · cited 2×
“Women’s clearance rates may be approximately 20% higher than men’s [68].”
InfluentialLimbic-frontal circuitry in major depression: a path modeling metanalysis
Seminowicz, D. A., Mayberg, H. S., McIntosh, A. R., Goldapple, K., Kennedy, S., Segal, Z., & Rafi-Tari, S. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.01.015 · Cited by 710
(2000) · PubMed · Cited by 685
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643 · cited 1×
“Moreover, Moda-Sava et al. highlighted that ketamine not only reversed dendritic spine loss but also rejuvenated disrupted microcircuits in the PFC, restoring both structure and function in this critical region affected by chronic stress [166].”
Wise, T., Radua, J., Via, E., Cardoner, N., Abe, O., Adams, T. M., Amico, F., Cheng, Y., Cole, J. H., de Azevedo Marques Périco, C., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.72 · Cited by 606 · cited 1×
“In addition, Wise et al. revealed in their metanalysis that smaller volumes of grey matter in the right dlPFC and left hippocampus were more significant in patients with MDD than in controls [202].”
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Rajkowska, G., & Stockmeier, C. (2013) · Current Drug Targets · doi:10.2174/13894501113149990156 · Cited by 603 · cited 1×
“In MDD, consistent pathology shows reduced expression of GFAP and altered astrocyte function, affecting glutamate uptake and synaptic development [151].”
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 2×
“Depending on the location of their activation—either synaptic or extrasynaptic—NMDA receptors can trigger neurotrophic pathways, such as those mediated by brain-derived neurotrophic factor (BDNF) or apoptotic pathways [87,88].”
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 564
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537 · cited 1×
“This inhibitory action subsequently liberates mTOR Complex 1 (mTORC1) from its regulatory constraints. mTORC1 then phosphorylates downstream targets including p70S6K and 4E-BP1 (see Figure 3) [105,143].”
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide
Savitz, J., & Drevets, W. C. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.01.004 · Cited by 494
Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484 · cited 2×
“Moreover, lower synaptic density was found in the dorsolateral prefrontal cortex (dlPFC), anterior cingulate cortex (ACC), and hippocampus using PET with radioligand glycoprotein 2A synaptic vesicles [78,157].”
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482 · cited 2×
“Depending on the location of their activation—either synaptic or extrasynaptic—NMDA receptors can trigger neurotrophic pathways, such as those mediated by brain-derived neurotrophic factor (BDNF) or apoptotic pathways [87,88].”
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 1×
“The onset of action typically occurs within 5–40 min, with peak effects observed around 40 min post-administration [56,57].”
Ferrari, A. J., Norman, R. E., Freedman, G., Baxter, A. J., Pirkis, J. E., Harris, M. G., Page, A., Carnahan, E., Degenhardt, L., Vos, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091936 · Cited by 480
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Liu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
Volumetric reduction in left subgenual prefrontal cortex in early onset depression
Botteron, K. N., Raichle, M. E., Drevets, W. C., Heath, A. C., & Todd, R. D. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01280-x · Cited by 371
Boldrini, M., Santiago, A. N., Hen, R., Dwork, A. J., Rosoklija, G. B., Tamir, H., Arango, V., & John Mann, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.5 · Cited by 361
Miller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358 · cited 1×
“This effect is proposed to result from the selective blockade of NMDARs containing GluN2B subunits [98].”
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Overview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 329
Mechanism of action of antidepressant medications.
Feighner, J. P. (1999) · PubMed · Cited by 323
Structure, Function, and Pharmacology of NMDA Receptor Channels
VYKLICKY, V., KORINEK, M., SMEJKALOVA, T., BALIK, A., KRAUSOVA, B., KANIAKOVA, M., LICHNEROVA, K., CERNY, J., KRUSEK, J., DITTERT, I., et al. (2014) · Physiological Research · doi:10.33549/physiolres.932678 · Cited by 321
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Walter, M., Henning, A., Grimm, S., Schulte, R. F., Beck, J., Dydak, U., Schnepf, B., Boeker, H., Boesiger, P., & Northoff, G. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.39 · Cited by 306
Hosang, G. M., Shiles, C., Tansey, K. E., McGuffin, P., & Uher, R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-7 · Cited by 292 · cited 1×
“In contrast, Hosang et al. study showed no interactions between BDNF Val66Met polymorphism and life stress in depression [169].”
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Horn (2010) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2010.00033 · Cited by 276
MacQueen, G. M., Yucel, K., Taylor, V. H., Macdonald, K., & Joffe, R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.027 · Cited by 274 · cited 1×
“According to this theory, chronic stress leads to a decrease in neuroprotective factors, resulting in damaged or impaired plasticity, neuronal atrophy, and a reduction in synapses and their function, especially in these critical structures [216–218].”
NOLAN, M., MALLERET, G., DUDMAN, J., BUHL, D., SANTORO, B., GIBBS, E., VRONSKAYA, S., BUZSAKI, G., SIEGELBAUM, S., & KANDEL, E. (2004) · Cell · doi:10.1016/s0092-8674(04)01055-4 · Cited by 274
Tripp, A., Oh, H., Guilloux, J.-P., Martinowich, K., Lewis, D. A., & Sibille, E. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020248 · Cited by 273 · cited 1×
“A mechanism of down-regulation of several GABA-related genes has been found in the sgACC of patients with major depression, resulting in lower levels of GABA and potentially affecting dendritic somatostatin targeting interneurons [194,195].”
Tyler, W. J., & Pozzo‐Miller, L. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.052639 · Cited by 267
Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi‐Pavlovic, D., Leyden, J., Harper, S., Somogyi, A. A., Lai, R., Weickert, C. S., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12572 · Cited by 257
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256 · cited 2×
“Furthermore, the increased level of BDNF in plasma may be linked to treatment [135].”
Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Moitra, M., Santomauro, D., Degenhardt, L., Collins, P. Y., Whiteford, H., Vos, T., & Ferrari, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.053 · Cited by 252
Jessen, K. R. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.023 · Cited by 252
Gideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232 · cited 1×
“Moreover, ketamine’s activity-independent blockade of NMDARs reduces phosphorylation of eukaryotic elongation factor 2 (eEF2), which, in turn, enhances BDNF expression and supports synaptic formation [92,93].”
Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
Shulman, K. I., Herrmann, N., & Walker, S. E. (2013) · CNS Drugs · doi:10.1007/s40263-013-0097-3 · Cited by 227
Ibrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 1×
“However, the functional relevance of the different splice forms remains uncertain [83–85].”
In vivo detection of GABA and glutamate with MEGA‐PRESS: Reproducibility and gender effects
O'Gorman, R. L., Michels, L., Edden, R. A., Murdoch, J. B., & Martin, E. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22520 · Cited by 219
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Structural basis of ketamine action on human NMDA receptors
Zhang, Y., Ye, F., Zhang, T., Lv, S., Zhou, L., Du, D., Lin, H., Guo, F., Luo, C., & Zhu, S. (2021) · Nature · doi:10.1038/s41586-021-03769-9 · Cited by 218
Li, C.-T., Lin, C.-P., Chou, K.-H., Chen, I.-Y., Hsieh, J.-C., Wu, C.-L., Lin, W.-C., & Su, T.-P. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.021 · Cited by 213
Oberlander, J. G., & Woolley, C. S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4437-15.2016 · Cited by 213
Miller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200 · cited 1×
“Miller et al. hypothesize that direct antagonism of NMDARs on pyramidal neurons (PNs) triggers a protein synthesis-dependent, cell-autonomous form of homeostatic synaptic plasticity, leading to an increase in excitatory synaptic input onto these neurons [97].”
Reduced somatostatin in subgenual anterior cingulate cortex in major depression
Tripp, A., Kota, R. S., Lewis, D. A., & Sibille, E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.014 · Cited by 190
Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
Deyama, S., & Duman, R. S. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172837 · Cited by 186 · cited 3×
“Postmortem analyses have also observed reduced neuronal size and thickness of the cerebral cortex, especially in the medial and orbital areas in the PFC [159,160], and fewer granule cells in the dentate gyrus of the hippocampus in depressed individuals [161,162].”
Evidence for glutamate‐mediated activation of hippocampal neurons by glial calcium waves
Hassinger, T. D., Atkinson, P. B., Strecker, G. J., Whalen, L. R., Dudek, F. E., Kossel, A. H., & Kater, S. B. (1995) · Journal of Neurobiology · doi:10.1002/neu.480280204 · Cited by 182
Metabolism and metabolomics of ketamine: a toxicological approach
Dinis-Oliveira, R. J. (2017) · Forensic Sciences Research · doi:10.1080/20961790.2017.1285219 · Cited by 178
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175 · cited 4×
“A series of magnetic resonance imaging (MRI) studies have shown a reduction in the volume of both the PFC and hippocampus by up to about 19% in patients with MDD [78,154,155], and positron emission tomography (PET) reduced metabolism in PFC [78,156].”
InfluentialHughes, E. G., Maguire, J. L., McMinn, M. T., Scholz, R. E., & Sutherland, M. L. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.02.021 · Cited by 174
Tizabi, Y., Bhatti, B. H., Manaye, K. F., Das, J. R., & Akinfiresoye, L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.052 · Cited by 173
Evans, J. W., Szczepanik, J., Brutsché, N., Park, L. T., Nugent, A. C., & Zarate, C. A. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.027 · Cited by 173 · cited 1×
“Connectivity alterations in the insula among subjects with MDD imply that ketamine may normalize the interplay between the DMN and SN [205].”
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171 · cited 1×
“However, whether this mechanism accounts for the drug’s long-term antidepressant effects remains unclear [95].”
Zhao, M., Chen, L., Yang, J., Han, D. H., Fang, D., Qiu, X., Yang, X., Qiao, Z., Ma, J., Wang, L., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.024 · Cited by 170
Liu, W., Wang, J., Xie, Z.-M., Xu, N., Zhang, G.-F., Jia, M., Zhou, Z., Hashimoto, K., & Yang, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4128-2 · Cited by 169
Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders
Croom, K. F., Perry, C. M., & Plosker, G. L. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00006 · Cited by 158
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916570117 · Cited by 156 · cited 1×
“Their findings suggest that ketamine’s therapeutic action depends on both NMDA and opioid receptor signaling, not as a direct opioid agonist [172].”
Correia, A. S., Cardoso, A., & Vale, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082081 · Cited by 155
Li, C., Chen, M., Lin, W., Hong, C., Yang, B., Liu, R., Tu, P., & Su, T. (2016) · Human Brain Mapping · doi:10.1002/hbm.23085 · Cited by 152 · cited 1×
“Most impor-Int tantly, neuroimaging data suggested that increased glutamatergic neurotransmission in the PFC was critical to the ketamine-specific rapid antidepressant effect [210].”
Akinfiresoye, L., & Tizabi, Y. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3153-2 · Cited by 149
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 148
Millan, M. J., Gobert, A., Lejeune, F., Newman-Tancredi, A., Rivet, J.-M., Auclair, A., & Peglion, J.-L. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29415-5 · Cited by 146
Kohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
Metabolism of Ketamine Stereoisomers by Human Liver Microsomes
Kharasch, E. D., & Labroo, R. (1992) · Anesthesiology · doi:10.1097/00000542-199212000-00022 · Cited by 137
Zhao, X., Venkata, S. L. V., Moaddel, R., Luckenbaugh, D. A., Brutsche, N. E., Ibrahim, L., Zarate Jr, C. A., Mager, D. E., & Wainer, I. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04198.x · Cited by 137
Ihmsen, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.119722 · Cited by 136
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122 · cited 2×
“…nefazodone, interact with the α 1-adrenergic receptor, resulting in the inhibition of 5-HT and NE reuptake [30], while specific serotonergic antidepressants (NASSAs), including mirtazapine, are antagonists of presynaptic α 2-adrenergic autoreceptors and selectively inhibit 5-HT2 and 5-HT3 [27,31].”
Boldrini, M., Galfalvy, H., Dwork, A. J., Rosoklija, G. B., Trencevska-Ivanovska, I., Pavlovski, G., Hen, R., Arango, V., & Mann, J. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.022 · Cited by 116
El-Bakri, N., Islam, A., Zhu, S., Elhassan, A. M., Mohammed, A. K., Winblad, B. G., & Adem, A. (2004) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2004.tb00478.x · Cited by 115
Shiroma, P. R., Thuras, P., Wels, J., Albott, C. S., Erbes, C., Tye, S., & Lim, K. O. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00897-0 · Cited by 112
Jelks, K. B., Wylie, R., Floyd, C. L., McAllister, A. K., & Wise, P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0909-07.2007 · Cited by 111
Henssler, J., Alexander, D., Schwarzer, G., Bschor, T., & Baethge, C. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4313 · Cited by 111 · cited 1×
“Also, mianserin, which belongs to the tetracyclic antidepressants (TeCAs), and tra-zodone, which belongs to SARI, block presynaptic α 2 autoreceptors [32].”
Sex Differences in Psychiatric Disease: A Focus on the Glutamate System
Wickens, M. M., Bangasser, D. A., & Briand, L. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00197 · Cited by 110
McIntyre, R. S., Rodrigues, N. B., Lee, Y., Lipsitz, O., Subramaniapillai, M., Gill, H., Nasri, F., Majeed, A., Lui, L. M. W., Senyk, O., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.088 · Cited by 110
Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals
Mkrtchian, A., Evans, J. W., Kraus, C., Yuan, P., Kadriu, B., Nugent, A. C., Roiser, J. P., & Zarate, C. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00878-1 · Cited by 110
Moaddel, R., Venkata, S. L. V., Tanga, M. J., Bupp, J. E., Green, C. E., Iyer, L., Furimsky, A., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2010) · Talanta · doi:10.1016/j.talanta.2010.08.005 · Cited by 108
Functional parcellation of the default mode network: a large-scale meta-analysis
Wang, S., Tepfer, L. J., Taren, A. A., & Smith, D. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-72317-8 · Cited by 102
Functional MRI findings, pharmacological treatment in major depression and clinical response
Arnone, D. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.08.004 · Cited by 99
Zhang, K., Xu, T., Yuan, Z., Wei, Z., Yamaki, V. N., Huang, M., Huganir, R. L., & Cai, X. (2016) · Science Signaling · doi:10.1126/scisignal.aai7884 · Cited by 98 · cited 1×
“Inhibition of extrasynaptic NMDARs along with the concurrent activation of postsynaptic AMPA receptors facilitates the initiation of signaling pathways related to neuroplasticity [102].”
Wang, Y., Ma, Y., Hu, J., Cheng, W., Jiang, H., Zhang, X., Li, M., Ren, J., & Li, X.-M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.008 · Cited by 97
Sex differences in the glutamate system: Implications for addiction
Giacometti, L. L., & Barker, J. M. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.010 · Cited by 95
Rybakowski, J. K., Permoda‐Osip, A., Skibinska, M., Adamski, R., & Bartkowska‐Sniatkowska, A. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2271 · Cited by 93
In vivo glutamate measured with magnetic resonance spectroscopy: behavioral correlates in aging
Zahr, N. M., Mayer, D., Rohlfing, T., Chanraud, S., Gu, M., Sullivan, E. V., & Pfefferbaum, A. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.014 · Cited by 93
Saland, S. K., & Kabbaj, M. (2018) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.251652 · Cited by 93
Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus
Ardalan, M., Rafati, A. H., Nyengaard, J. R., & Wegener, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13714 · Cited by 92
The clinical toxicology of ketamine
Schep, L. J., Slaughter, R. J., Watts, M., Mackenzie, E., & Gee, P. (2023) · Clinical Toxicology · doi:10.1080/15563650.2023.2212125 · Cited by 88
The Altered Triple Networks Interaction in Depression under Resting State Based on Graph Theory
Zheng, H., Xu, L., Xie, F., Guo, X., Zhang, J., Yao, L., & Wu, X. (2015) · BioMed Research International · doi:10.1155/2015/386326 · Cited by 82
A new resolution for global mental health
Hock, R. S., Or, F., Kolappa, K., Burkey, M. D., Surkan, P. J., & Eaton, W. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60243-8 · Cited by 80
Meshkat, S., Alnefeesi, Y., Jawad, M. Y., Vincenzo, J. D. D., Rodrigues, N. B., Ceban, F., Lui, L. M. W., McIntyre, R. S., & Rosenblat, J. D. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114857 · Cited by 79
Chen, M.-H., Lin, W.-C., Tu, P.-C., Li, C.-T., Bai, Y.-M., Tsai, S.-J., & Su, T.-P. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.022 · Cited by 78
Müller, F., Musso, F., London, M. K., de Boer, P., Zacharias, N., & Winterer, G. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.05.037 · Cited by 75
Structural core of the executive control network: A high angular resolution diffusion MRI study
Shen, K., Welton, T., Lyon, M., McCorkindale, A. N., Sutherland, G. T., Burnham, S., Fripp, J., Martins, R., & Grieve, S. M. (2020) · Human Brain Mapping · doi:10.1002/hbm.24870 · Cited by 75
Luo, T., Deng, Z., Ren, Q., Mu, F., Zhang, Y., & Wang, H. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111447 · Cited by 75
Treccani, G., Ardalan, M., Chen, F., Musazzi, L., Popoli, M., Wegener, G., Nyengaard, J. R., & Müller, H. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1613-3 · Cited by 73 · cited 1×
“Treccani et al.’s study on rodents showed that ketamine restored dendritic spines in the hippocampal CA1 region within 1 h of administration [164].”
Li, M., Demenescu, L. R., Čolić, L., Metzger, C. D., Heinze, H., Steiner, J., Speck, O., Fejtová, A., Salvadore, G., & Walter, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.184 · Cited by 72
Zlotnik, A. A., Gruenbaum, B. F., Mohar, B., Kuts, R., Gruenbaum, S. E., Ohayon, S., Boyko, M., Klin, Y., Sheiner, E., Shaked, G., et al. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.110.088120 · Cited by 71
Lack of Opioid System in the Antidepressant Actions of Ketamine
Zhang, K., & Hashimoto, K. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.11.006 · Cited by 71
Picard, N., Takesian, A. E., Fagiolini, M., & Hensch, T. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0341-9 · Cited by 71 · cited 2×
“During the follicular phase, when estradiol levels are low, ketamine’s effects are transient and weaker compared to the luteal phase, where estradiol (active form of estrogen) levels are high [120].”
The pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69 · cited 1×
“…as tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reup-take inhibitors (SSRIs), and norepinephrine reuptake inhibitors (SNRIs), act by regulating monoamines in the central nervous system, increasing serotonergic and noradrenergic neurotransmission [16].”
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Gärtner, M., Aust, S., Bajbouj, M., Fan, Y., Wingenfeld, K., Otte, C., Heuser-Collier, I., Böker, H., Hättenschwiler, J., Seifritz, E., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.008 · Cited by 66
Ponton, E., Turecki, G., & Nagy, C. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab082 · Cited by 65
Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action
Du, J., Machado-Vieira, R., Maeng, S., Martinowich, K., Manji, H. K., & Zarate, C. A. (2006) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2006.11.012 · Cited by 64
Woelfer, M., Li, M., Colic, L., Liebe, T., Di, X., Biswal, B., Murrough, J., Lessmann, V., Brigadski, T., & Walter, M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1679391 · Cited by 64 · cited 1×
“In some cases, ketamine and esketamine administration did not correlate with changes in serum or plasma BDNF levels, while other studies found that ketamine significantly increased plasma or serum BDNF [128–135].”
The genetics of selective serotonin reuptake inhibitors
Kroeze, Y., Zhou, H., & Homberg, J. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.015 · Cited by 60
Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects
Li, M., Woelfer, M., Čolić, L., Safron, A., Chang, C., Heinze, H., Speck, O., Mayberg, H. S., Biswal, B. B., Salvadore, G., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0942-y · Cited by 60
Dynamic functional connectivity profile of the salience network across the life span
Snyder, W. E., Uddin, L. Q., & Nomi, J. S. (2021) · Human Brain Mapping · doi:10.1002/hbm.25581 · Cited by 60
Kopelman, J., Keller, T. A., Panny, B., Griffo, A., Degutis, M., Spotts, C., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02451-0 · Cited by 60
Reed, J. L., Nugent, A. C., Furey, M. L., Szczepanik, J. E., Evans, J. W., & Zarate, C. A. (2019) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.01.005 · Cited by 56 · cited 1×
“Furthermore, the activation pattern observed in MDD participants post-ketamine infusion mirrored the activation seen in healthy controls following a placebo infusion, indicating a potential normalization of functional dynamics during emotional processing [206].”
Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Xu, S., Yao, X., Li, B., Cui, R., Zhu, C., Wang, Y., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740996 · Cited by 56
Becker, G., Bolbos, R., Costes, N., Redouté, J., Newman-Tancredi, A., & Zimmer, L. (2016) · Scientific Reports · doi:10.1038/srep26633 · Cited by 55
Subcutaneous Ketamine in Depression: A Systematic Review
Cavenaghi, V. B., da Costa, L. P., Lacerda, A. L. T., Hirata, E. S., Miguel, E. C., & Fráguas, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.513068 · Cited by 54
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 52
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
Ho, M.-F., Correia, C., Ingle, J. N., Kaddurah-Daouk, R., Wang, L., Kaufmann, S. H., & Weinshilboum, R. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.032 · Cited by 49 · cited 1×
“The primary concern with unop-posed estrogens appears to be the risk for endometrial carcinoma, which may suggest that monitoring postmenopausal women administered ketamine for endometrial irregularities would be judicious [110].”
Li, S., Luo, X., Hua, D., Wang, Y., Zhan, G., Huang, N., Jiang, R., Yang, L., Zhu, B., Yuan, X., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01702 · Cited by 49
Salience network engagement with the detection of morally laden information
Sevinc, G., Gurvit, H., & Spreng, R. N. (2017) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsx035 · Cited by 48
Novel Molecular Targets of Antidepressants
Jarończyk, M., & Walory, J. (2022) · Molecules · doi:10.3390/molecules27020533 · Cited by 48
Rucci, P., Frank, E., Scocco, P., Calugi, S., Miniati, M., Fagiolini, A., & Cassano, G. B. (2011) · Depression and Anxiety · doi:10.1002/da.20758 · Cited by 46
Fang, X., Zhang, Y., Zhou, Y., Cheng, L., Li, J., Wang, Y., Friston, K. J., & Jiang, T. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00027 · Cited by 45
Li, R., Zhang, S., Yin, S., Ren, W., He, R., & Li, J. (2018) · Human Brain Mapping · doi:10.1002/hbm.24247 · Cited by 43
Glue, P., Medlicott, N. J., Surman, P., Lam, F., Hung, N. A., & Hung, C. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1573 · Cited by 42
Glue, P., Neehoff, S., Beaglehole, B., Shadli, S. M., McNaughton, N., & Medlicott, N. J. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241227026 · Cited by 40
Chen, J.-X., Yao, L.-H., Xu, B.-B., Qian, K., Wang, H.-L., Liu, Z.-C., Wang, X.-P., & Wang, G.-H. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1362-5 · Cited by 39
Vilazodone: A Review in Major Depressive Disorder in Adults
McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0490-y · Cited by 39
Subcortical contributions to salience network functioning during negative emotional processing
Ince, S., Steward, T., Harrison, B. J., Jamieson, A. J., Davey, C. G., Agathos, J. A., Moffat, B. A., Glarin, R. K., & Felmingham, K. L. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.119964 · Cited by 39
Ardalan, M., Wegener, G., Rafati, A. H., & Nyengaard, J. R. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw098 · Cited by 37
Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Ianni, T. D., Ewbank, S. N., Levinstein, M. R., Azadian, M. M., Budinich, R. C., Michaelides, M., & Airan, R. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45157-7 · Cited by 37
Intramuscular ketamine in acute depression: A report on two cases
Harihar, C., Dasari, P., & Srinivas, J. (2013) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.111461 · Cited by 36
Elevated GFAP isoform expression promotes protein aggregation and compromises astrocyte function
Lin, N., Yang, A., Chang, C., & Perng, M. (2021) · The FASEB Journal · doi:10.1096/fj.202100087r · Cited by 36
Ju, L.-S., Yang, J., Zhu, T., Liu, P., & Yang, J. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03838-x · Cited by 36
Alexander, L., Hawkins, P. C. T., Evans, J. W., Mehta, M. A., & Zarate, C. A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02674-1 · Cited by 36
Höflich, A., Kraus, C., Pfeiffer, R. M., Seiger, R., Rujescu, D., Zarate, C. A., Kasper, S., Winkler, D., & Lanzenberger, R. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01318-6 · Cited by 34
Chen, M.-H., Kao, C.-F., Tsai, S.-J., Li, C.-T., Lin, W.-C., Hong, C.-J., Bai, Y.-M., Tu, P.-C., & Su, T.-P. (2021) · Genomics · doi:10.1016/j.ygeno.2020.12.030 · Cited by 33
Acute stress alters recognition memory and AMPA/NMDA receptor subunits in a sex-dependent manner
Torrisi, S. A., Rizzo, S., Laudani, S., Ieraci, A., Drago, F., & Leggio, G. M. (2023) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100545 · Cited by 33
Wang, P., Neiner, A., & Kharasch, E. D. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002371 · Cited by 31
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors
Gomes, I., Gupta, A., Margolis, E. B., Fricker, L. D., & Devi, L. A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000947 · Cited by 30
NMDARs, Coincidence Detectors of Astrocytic and Neuronal Activities
Sherwood, M. W., Oliet, S. H. R., & Panatier, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147258 · Cited by 29
Tonic NMDA Receptor Currents in the Brain: Regulation and Cognitive Functions
Kim, H., Choi, S., Lee, E., Koh, W., & Lee, C. J. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.03.009 · Cited by 29
Ketamine for Depression, 2: Diagnostic and Contextual Indications
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11629 · Cited by 28
Chen, M.-H., Chang, W.-C., Lin, W.-C., Tu, P.-C., Li, C.-T., Bai, Y.-M., Tsai, S.-J., Huang, W.-S., & Su, T.-P. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa056 · Cited by 28
Lipsitz, O., McIntyre, R. S., Rodrigues, N. B., Lee, Y. L., Gill, H., Subramaniapillai, M., Kratiuk, K., Nasri, F., Mansur, R. B., & Rosenblat, J. D. (2020) · CNS Spectrums · doi:10.1017/s1092852920002102 · Cited by 27
Cannarozzo, C., Rubiolo, A., Casarotto, P., & Castrén, E. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15929 · Cited by 25
Clinical Efficacy of Ketamine for Treatment-resistant Depression
Bratsos, S., & Saleh, S. N. (2019) · Cureus · doi:10.7759/cureus.5189 · Cited by 24
Adžić, M., Lukić, I., Mitić, M., Glavonic, E., Dragicevic-Curic, N., & Ivković, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121803 · Cited by 24
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
Colla, M., Offenhammer, B., Scheerer, H., Kronenberg, G., Vetter, S., Mutschler, J., Mikoteit, T., Bankwitz, A., Adank, A., Schaekel, L., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.002 · Cited by 23
Lewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
Tseng, H.-J., Lu, C., Jeng, J., Cheng, C., Chu, J.-W., Chen, M., Bai, Y., Tsai, S., Su, T., & Li, C. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210131 · Cited by 19
Cavaleri, D., Riboldi, I., Crocamo, C., Paglia, G., Carrà, G., & Bartoli, F. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137791 · Cited by 19
Li, Y., Dai, X., Wu, H., & Wang, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.729958 · Cited by 16
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
Comparing the adverse effects of ketamine and esketamine between genders using FAERS data
Yang, X., & Chen, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1329436 · Cited by 16
Li, Y., Qian, L., Li, G., & Zhang, Z. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1200029 · Cited by 15
Research works printed but not linked: 2
- Delgado, 2000, Depression: The case for a monoamine deficiency, J. Clin. Psychiatry, 61, 7
- Depukat, 2024, Polski standard leczenia racemiczną ketaminą pacjentów z zaburzeniami depresyjnymi opracowany przez zespół roboczy powołany przez Konsultanta Krajowegow dziedzinie psychiatrii, Psychiatr. Pol., 58, 377
Cited by
Nagpurkar, K., Ghive, P., Kale, M. B., Nistane, N. T., Taksande, B. G., Umekar, M. J., & Trivedi, R. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.05.022 · Cited by 12
Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors
Oatu, A., Trifu, S. C., & Coman, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311325 · Cited by 10
Azadbakht, A. A., Mashayekhi‐Sardoo, H., & Baghcheghi, Y. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04619-0 · Cited by 6
Yao, Z., Godje, I. S. G., Jiao, B., Shen, L., & Luo, S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103153 · Cited by 6
Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?
Lu, A., Xu, H., Le, G. H., Dri, C. E., Wong, S., Ho, R., Cao, B., Lo, H. K. Y., Rhee, T. G., Yin, L., et al. (2026) · European Psychiatry · doi:10.1192/j.eurpsy.2026.10157 · Cited by 6
Metadata
- Authors
- Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P.
- Affiliations
- Medical University of Białystok (PL)
- Corresponding author
- Jakubów, Piotr
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-12-20
- Volume
- 25
- Issue
- 24
- Pages
- 13658
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11728282
- OpenAlex
- W4405695206
- Cited by
- 21
- References
- 225
- Citations by year
- 2026: 15 · 2025: 6
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, depression, rapid-acting antidepressants, NMDA receptor antagonism, glutamate, AMPA receptors, BDNF/TrkB signaling, mTOR signaling, synaptic plasticity, default mode network, frontoparietal network, salience network, opioid receptors, BDNF polymorphism, treatment response
- MeSH terms
- Animals, Antidepressive Agents, Brain, Depression, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Brain-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.